Celastrol induces DNA damage and cell death in BCR-ABL T315I-mutant CML by targeting YY1 and HMCES
Authors:
- 8 August 2024
- journal article
- research article
- Published by Elsevier in Phytomedicine
- Vol. 134, 155937
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019Cancer, 2023
- Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategiesBiomedicine & Pharmacotherapy, 2023
- A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routesBiomedicine & Pharmacotherapy, 2023
- Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoringAmerican Journal of Hematology, 2022
- Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitorsAmerican Journal of Hematology, 2022
- Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1Acta Pharmaceutica Sinica B, 2021
- Recent advances in proteome‐wide label‐free target deconvolution for bioactive small moleculesMedicinal Research Reviews, 2021
- Celastrol, a novel HSP90 inhibitor, depletes Bcr–Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutationCancer Letters, 2010
- Molecular Understanding and Modern Application of Traditional Medicines: Triumphs and TrialsCell, 2007
- Transcription Factor Yin Yang 1 Stimulates Poly(ADP-Ribosyl)ation and DNA RepairBiochemical and Biophysical Research Communications, 2001